Sei Investments Co. Buys 185,271 Shares of Solventum Corporation $SOLV

Sei Investments Co. boosted its stake in shares of Solventum Corporation (NYSE:SOLV) by 335.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 240,581 shares of the company’s stock after acquiring an additional 185,271 shares during the quarter. Sei Investments Co.’s holdings in Solventum were worth $15,711,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in SOLV. Measured Wealth Private Client Group LLC bought a new position in Solventum during the 3rd quarter valued at about $25,000. CrossGen Wealth LLC acquired a new position in Solventum in the fourth quarter valued at about $25,000. Clearstead Trust LLC grew its stake in Solventum by 61.0% during the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock worth $26,000 after buying an additional 150 shares during the last quarter. JNBA Financial Advisors grew its position in Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after acquiring an additional 228 shares during the last quarter. Finally, CYBER HORNET ETFs LLC bought a new stake in shares of Solventum during the second quarter worth $28,000.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SOLV shares. Wedbush began coverage on Solventum in a research note on Friday, May 15th. They issued an “outperform” rating and a $94.00 target price for the company. Piper Sandler cut their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. UBS Group upgraded shares of Solventum from a “neutral” rating to a “buy” rating and set a $95.00 price objective for the company in a report on Tuesday. KeyCorp upped their target price on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, Wells Fargo & Company cut their target price on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 6th. Seven equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $86.00.

Solventum Stock Down 1.8%

Solventum stock opened at $86.97 on Friday. The stock has a market capitalization of $15.06 billion, a PE ratio of 10.66, a price-to-earnings-growth ratio of 1.37 and a beta of 0.66. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $88.65. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The company has a 50 day moving average of $78.24 and a 200-day moving average of $74.20.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The firm’s quarterly revenue was down 3.0% on a year-over-year basis. During the same period last year, the business posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.